Patents by Inventor Steve Holmes

Steve Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-OPG ANTIBODIES
    Publication number: 20260103533
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Application
    Filed: September 15, 2025
    Publication date: April 16, 2026
    Inventors: Joana DE ABREU CARVALHO, Steve HOLMES, Allan LAWRIE
  • Anti-OPG antibodies
    Patent number: 12473371
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: November 18, 2025
    Assignee: KYMAB LIMITED
    Inventors: Joana De Abreu Carvalho, Steve Holmes, Allan LAwrie
  • ANTIBODIES, USES & METHODS
    Publication number: 20250263492
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: January 17, 2025
    Publication date: August 21, 2025
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • Antigen binding molecules that bind LIGHT
    Patent number: 12227580
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: February 18, 2025
    Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED
    Inventor: Steve Holmes
  • ANTIGEN BINDING MOLECULES THAT BIND LIGHT
    Publication number: 20240294655
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14), competing with LIGHT binding to cellular receptors Herpes virus entry mediator (HVEM) and lymphotoxin beta receptor, and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Application
    Filed: October 3, 2023
    Publication date: September 5, 2024
    Inventor: Steve HOLMES
  • Compositions monovalent for CD28 binding and methods of use
    Patent number: 12012452
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: June 18, 2024
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • ANTIBODIES, USES & METHODS
    Publication number: 20240132605
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: August 3, 2023
    Publication date: April 25, 2024
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • ANTI-OPG ANTIBODIES
    Publication number: 20240026020
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Application
    Filed: May 5, 2023
    Publication date: January 25, 2024
    Inventors: Joana DE ABREU CARVALHO, Steve HOLMES, Allan LAWRIE
  • Antigen binding molecules that bind light
    Patent number: 11827673
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14), competing with LIGHT binding to cellular receptors Herpes virus entry mediator (HVEM) and lymphotoxin beta receptor, and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 28, 2023
    Assignee: CAPELLA BIOSCIENCE LTD
    Inventor: Steve Holmes
  • Antibodies, uses and methods
    Patent number: 11773175
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: October 3, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Nucleic acids encoding anti-OX40L antibodies
    Patent number: 11753479
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: September 12, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • THERAPEUTIC ANTIBODIES
    Publication number: 20230272097
    Abstract: The invention relates to antibodies which modulate the OX40 signalling pathway to treat inflammatory diseases in companion animals, for example atopic dermatitis (AD) and/or eczema. Related methods and uses are also described.
    Type: Application
    Filed: August 6, 2021
    Publication date: August 31, 2023
    Inventors: Allan BRADLEY, Andrew James THOMPSON, Daniel John BOLLAND, Juexuan WANG, Roberto BANDIERA, Steve HOLMES
  • Anti-OPG antibodies
    Patent number: 11680101
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 20, 2023
    Assignee: KYMAB LIMITED
    Inventors: Joana De Abreu Carvalho, Steve Holmes, Allan Lawrie
  • Antigen Binding Molecules That Bind LIGHT
    Publication number: 20230035798
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Application
    Filed: April 22, 2022
    Publication date: February 2, 2023
    Inventor: Steve Holmes
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20220372153
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 24, 2022
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20220356255
    Abstract: The present invention relates to antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the programmed death-ligand 1 (PD-L1) in a pH-dependant manner, competing with PD-L1 binding to the inhibitory receptor programmed death 1 polypeptide (PD-1) and co-stimulatory molecule CD80, and the use of said antigen binding molecules in treating and/or preventing diseases such as cancer.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 10, 2022
    Inventor: Steve HOLMES
  • Methods of treating comprising administering anti-OX40L antibodies
    Patent number: 11396550
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 26, 2022
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • ANTI BDCA-2 ANTIBODIES
    Publication number: 20220162322
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to BDCA-2 (CLEC4C), and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders such as autoimmune diseases.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 26, 2022
    Inventor: Steve HOLMES
  • Antigen binding molecules that bind LIGHT
    Patent number: 11312781
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Capella BioScience Ltd.
    Inventor: Steve Holmes
  • Anti-human OX40L antibodies and methods of treatment
    Patent number: RE50880
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: May 5, 2026
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac